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Abstract
Background: Pegylated interferon plus ribavirin therapy for hepatitis C virus (HCV) fails in approximately half of genotype 1
patients. Treatment failure occurs either by nonresponse (minimal declines in viral titer) or relapse (robust initial responses
followed by rebounds of viral titers during or after therapy). HCV is highly variable genetically. To determine if viral genetic
differences contribute to the difference between response and relapse, we examined the inter-patient genetic diversity and
mutation pattern in the full open reading frame HCV genotype 1a consensus sequences.
Methodology/Principal Findings: Pre- and post-therapy sequences were analyzed for 10 nonresponders and 10 relapsers
from the Virahep-C clinical study. Pre-therapy interpatient diversity among the relapsers was higher than in the
nonresponders in the viral NS2 and NS3 genes, and post-therapy diversity was higher in the relapsers for most of HCV’s ten
genes. Pre-therapy diversity among the relapsers was intermediate between that of the non-responders and responders to
therapy. The average mutation rate was just 0.9% at the amino acid level and similar numbers of mutations occurred in the
nonresponder and relapser sequences, but the mutations in NS2 of relapsers were less conservative than in nonresponders.
Finally, the number and distribution of regions under positive selection was similar between the two groups, although the
nonresponders had more foci of positive selection in E2.
Conclusions/Significance: The HCV sequences were unexpectedly stable during failed antiviral therapy, both nonresponder
and relapser sequences were under selective pressure during therapy, and variation in NS2 may have contributed to the
difference in response between the nonresponder and relapser groups. These data support a role for viral genetic variability
in determining the outcome of anti-HCV therapy, with those sequences that are more distant from an optimal sequence
being less able to resist the pressures of interferon-based therapy.
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Introduction
Hepatitis C Virus (HCV) infects over 170 million people
worldwide and more than 4 million in the USA [1–3]. The costs
related to HCV infection in the United States are over $700
million annually [4], and the impact of HCV infection is expected
to rise over the next 20 years. Current therapy for HCV employs
pegylated interferon a and ribavirin, but treatment clears the
infection in only about half of patients infected with genotype 1,
the most common genotype in the USA [5–7]. The reasons for
failure of treatment are not fully understood, but host, virus, and
immune response variables all correlate with response to therapy
[5,8].
HCV is a Hepacivirus in the Flaviviridae family. Its genome is a
,9600 nucleotide, positive polarity single stranded RNA which
contains a single large open-reading frame. The structural
proteins include the core protein, which forms the viral capsid,
and two surface glycoproteins, E1 and E2. Nonstructural
proteins include a putative ion channel (p7), an autoprotease
(NS2), a protease/helicase (NS3/4A), a putative organizer of the
replication complex (NS4B), a pleiotropic regulatory protein
(NS5A), and an RNA-dependent RNA polymerase (NS5B). An
eleventh protein, the alternate reading frame protein, is encoded
in the +1 frame of the core gene and is of unknown function
[9–11].
HCV is highly genetically variable, with six different genotypes
that have less than 72% homology at the nucleotide level. Each
genotype is divided into multiple subtypes with 80-85% similarity.
Isolates within each subtype are also extremely variable, with
8-12% divergence between isolates from independent patients
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response to therapy because different genotypes respond to
therapy at different rates; genotype 2 responds to six months of
therapy over 80% of the time, while response in genotype 1 is
about 50% after 12 months of treatment [6,17–19]. Differences in
viral genetic variability in discrete protein regions have also been
linked to differences in response to therapy [15,19]. High variation
in the interferon-sensitivity determining region (ISDR) in NS5A
has been associated with response to interferon-based therapy in
some studies [20–23], and correlations between variations in the
PKR-eIF2 phosphorylation homology domain (PePHD) in E2 and
response to therapy have been noted [24–31]. Employing a full
open-reading frame sequencing strategy, we have shown that high
variation in genotype 1a NS3 and NS5A is associated with early
response to therapy [32].
There are at least two different patterns by which HCV
therapy can fail. Nonresponders have only minimal declines in
viral titers, while relapsers have robust declines followed by a
rebound in titers either during or after therapy. These different
patterns could be affected by many factors including host
genetics, immune response, and viral genetic differences
[6,8,18,19,33]. Viral genetic differences could include either
pre-therapy differences or differences that arise during treatment
due to viral evolution in response to the pressures applied by
therapy.
We previously reported that high pre-therapy inter-patient
variability in NS3 and NS5A correlated strongly with early
response to therapy in genotype 1a infected patients [32]. Here,
we hypothesized that there would be differences in pre-therapy
viral genetic variability between nonresponders and relapsers,
and that HCV sequences in the relapsers would have higher
rates of amino acid mutations than in nonresponders during
therapy since nonresponder sequences were relatively resistant at
the onset of therapy. To evaluate this hypothesis, we analyzed
pre- and post-therapy full open-reading frame sequences from 20
participants in the Virahep-C clinical study of factors affecting
response to antiviral therapy [8]; ten were nonresponders, and
ten were relapsers. The inter-patient variability among the
nonresponders and relapsers at pre-and post-therapy times was
compared, and the evolution of the virus over the course of
therapy was assessed.
Results
Experimental design and patient selection
The subjects in this study were chosen from the patients in the
Virahep-C viral genetics study who failed pegylated interferon a
and ribavirin therapy [32] infected with HCV genotype 1a for
whom samples were available for sequencing 6 months post-
therapy. Nonresponders had viral titers declines of #2.1 log10
IU/mL and absolute titers of $4.62 log10 IU/mL at nadir.
Relapsers had declines in viral titers of $2.8 log10 and their
absolute titers transiently dropped below the detection limit
(2.78 log10 IU/mL) (Figure 1). The baseline characteristics for
the two groups are shown in Table 1. There were no significant
differences in baseline characteristics (p,0.05) in any charac-
teristics except AFP, a nonspecific tumor marker, and the
Ishak necroinflammatory score, an indicator of liver inflamma-
tion. Interestingly, pre-therapy HCV RNA levels were not
predictive of the difference between relapse and nonresponse to
therapy.
Conserved positional differences between
nonresponders and relapsers
We first determined if there were consistent genetic differences
at discrete amino acid positions between the nonresponders and
relapsers. To do this, we created consensus sequences of the
nonresponder and relapser sequences at 60% conservation levels
for both pre- and post-therapy samples. The consensus
sequences for the nonresponder and relapser alignments were
Figure 1. Viral titers in relapsers and nonresponders during the first 24 weeks of therapy. Viral titers are shown as the log(titers [IU/mL])
at each time point. All relapsers (blue) dropped to the detection limit. One of the relapsers had a rebound of viral titers during the first 24 weeks. All
others had rebounds later in therapy. All nonresponders (red) declined by less than 2.1 log10.
doi:10.1371/journal.pone.0002123.g001
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consistently between the two phenotypes. For pre-therapy
sequences, nine positions differed between nonresponders and
relapsers (Table 2). In most of these cases, the dominant amino
acid in one group was the second most abundant amino acid in
the other group. In the post-therapy sequences, nine positions
differed, five of which were also found in the pre-therapy data.
All four positions that were novel in the post-therapy analysis
resulted from a single amino acid change during therapy that
caused the position to cross the 60% threshold. Likewise, the
pre-therapy positions that were not consistently different in post-
therapy samples were also all the result of single amino acid
changes in the samples except position 394, which is within
hypervariable region 1 (HVR1) in E2. The one exception to the
presence of the dominant amino acid in one phenotype being
present in the other group was at position 2283 [position 311 of
Table 1. Patient characteristics.
Nonresponder
a Relapser
a p-value
b
Age (years) 47.5 (45, 53) 48 (43, 49) 0.57
Male 8 8 1.00
Body weight (kg) 94.6 (89.4–103.4) 89.1 (77.6, 98.4) 0.22
African-American 5 4 1.00
HCV RNA (log10 IU/mL) 6.63 (6.45, 6.77) 6.52 (6.2, 6.68) 0.16
ALT (U/L) 71 (54, 104) 66.5 (54, 91) 0.96
Albumin (g/dL) 4.1 (4, 4.4) 4.2 (4.1, 4.6) 0.40
Platelet count (1000) 182.5 (161, 203) 204 (144, 225) 0.97
AFP 105 (95, 123) 65 (54, 83) 0.01
Ishak necroinflamatory score (0–18) 11.5 (11, 15) 7 (6, 11) 0.02
Ishak fibrosis score 3.5 (2, 4) 1.5 (1, 2) 0.09
a- numbers in brackets represent 25
th and 75
th percentile.
b- p-values are from permutation test based on 100,000 permutations, except for comparing proportion of males and proportion of African Americans for which Fisher’s
exact test was used.
doi:10.1371/journal.pone.0002123.t001
Table 2. Amino acid differences between nonresponders’ and relapsers’ consensus sequences at $60% conservation.
Position (Polyprotein) Protein Position Nonresponder Relapser
Primary Secondary Primary Secondary
Pre-therapy
394 E2 11 H R(2),K(1),Y(1) R H(2),F(1),S(1)
787 p7 41 V A(4) A V(3),T(1)
879 NS2 70 V A(2) A V(3)
1444 NS3 418 F Y(2) Y F(3)
2283 NS5A 311 P R(1) Q P(4)
2373 NS5A 401 P S(4) S P(2)
2413 NS5A 441 D G(4) G S(2),D(1)
2518 NS5B 98 K R(4) R K(4)
2720 NS5B 300 Q R(4) R Q(3),L(1)
Post-therapy
879 NS2 70 V A(2) A V(4)
929 NS2 120 A V(3),I(1) V A(4)
1412 NS3 386 I V(2),L(2) V I(4)
1444 NS3 418 F Y(3) Y F(4)
1686 NS4A 29 I V(4) V I(3)
2373 NS5A 401 P S(3) S P(2),T(1)
2411 NS5A 439 G E(4) E G(1)
2518 NS5B 98 K R(4) R K(4)
2720 NS5B 300 Q R(4) R Q(3),L(1)
Numbers in parentheses indicate the frequency of the secondary amino acids in the ten sequences.
doi:10.1371/journal.pone.0002123.t002
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356)] in pre-therapy sequences [34]. Proline was found at this
position in all but one of the nonresponders, which had an
arginine. However, proline was also found in 40% of relapsers
with the remaining 60% having glutamine.
Therefore, there were only a few amino acids that differed
consistently between the nonresponder and relapser sequences,
and these differences were relatively conserved after therapy.
However, the weak degree of conservation at these positions, the
common presence of the alternate amino acid from the opposing
phenotype, and the conservative nature of the alternate amino
acids at these positions all argue against variation at these positions
playing a major role in determining if the patient was a
nonresponder or relapser during therapy.
Inter-patient genetic diversity among the nonresponder
and relapser sequences
Since there were no amino acid positions at which genetic
differences strongly correlated with nonresponse or relapse, we
next examined the groups of sequences to determine if there were
differences in inter-patient diversity between the nonresponders
and relapsers that correlated with the response pattern. Diversity
differences were measured by comparing the numbers of amino
acid variations relative to a reference sequence and by measuring
differences in the average protein distances within the two groups.
First, each sample was aligned against an external genotype 1a
reference sequence [32], and positions of variation relative to the
reference were identified for each sample. Variations were
classified as unique to either relapsers or nonresponders if the
variation was observed in one group of sequences but not in the
other. In pre-therapy sequences, the polyproteins had similar
numbers of unique variations in nonresponders and relapsers
(Figure 2A). To determine if the variations were evenly distributed
throughout the polyprotein, we compared the number of
variations in each gene. Relapsers had significantly more unique
variations in NS2 than the nonresponders by the Mann-Whitney
test (p=0.048). All other proteins had similar numbers of unique
variations between the nonresponders and relapsers (p$0.05).
When the numbers of unique variations in the post-therapy
polyproteins were compared, relapsers had more unique variations
than nonresponders (p=0.006) (Figure 2B). Examination of the
individual genes revealed that there were more unique variations
in the relapsers in E2 (p=0.033), NS2 (p=0.027), and NS3
(p=0.045).
As a second measure of sample diversity, we compared the
average pair-wise protein distance within each group. The pair-
wise protein distances among the nonresponders and relapsers
were determined separately, and the mean protein distance for
each sample relative to the other nine nonresponder or relapser
sequences was determined. We then compared the average
distances among the nonresponders and relapsers and determined
their statistical significance using the Mann-Whitney test. In the
pre-therapy data (Figure 3A), relapsers had higher intra-group
genetic distances than nonresponders for the polyprotein
(p=0.049). When individual proteins were compared, the
relapsers had a higher average distance in core (p=0.007), NS2
(p=0.003), and NS3 (p=0.009), while the nonresponders had
higher average distance in P7 (p=0.041) and NS5A (p=0.019).
When the post-therapy samples were compared (Figure 3B),
relapsers had higher distances in the polyprotein (p=0.003), and
in core (p=0.001), E1 (p=0.010), NS2 (p=0.001), NS3
(p=0.001), NS4B (p=0.004), and NS5B (p=0.007). Therefore,
the relapsers had a higher overall protein distance than the
nonresponders in both pre- and post-therapy sequences, the
differences in protein distance were broadly distributed through
the polyprotein, and the differences were more pronounced in
post-therapy samples.
We next asked whether the greater differences between
nonresponders and relapsers in the post-therapy analysis were
due to changes in sequences from the nonresponders, relapsers, or
both by comparing the pre- versus post-therapy protein distances
among the nonresponders and relapsers (Figure 4). The protein
distance among nonresponders declined significantly in core
(p=0.006) and NS4A (p=0.027) in the nonresponders during
therapy, while the other proteins did not change significantly.
Relapsers had a different pattern. Core (p=0.046), E1 (p=0.006),
NS4B (p=0.023), and NS5A (p=0.041) had statistically signifi-
cant increases in protein distance during therapy, and many of the
other proteins, including the polyprotein, had increases that did
Figure 2. Unique amino acid variability among nonresponders
and relapsers. Amino acid variations found exclusively in one
response class but not in the other were compared between
nonresponders and relapsers. Statistical significance of the difference
in the number of variations was compared using the Mann-Whitney
test. A) Pre-therapy. B) Post-therapy. The line represents the median
value, and the box represents the 25–75% range. Whiskers represent
samples within 1.5 box lengths, and the u and * represent outliers
between 1.5 and 3 box lengths and beyond 3 box lengths respectively.
doi:10.1371/journal.pone.0002123.g002
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declined slightly in nonresponders during therapy, whereas they
increased substantially in relapsers.
Finally, the inter-patient protein distance of pre-therapy
sequences among nonresponders, relapsers, and responders was
compared to the distance among sustained viral responders to
antiviral therapy in the Virahep-C study [32] to determine how
the patterns observed in nonresponders and relapsers compared to
sequences that were responsive to pegylated interferon a and
ribavirin therapy. The intra-group distances of responders were
plotted in Figure 5 along with the nonresponders and relapsers.
Two patterns were most common. First, in the polyprotein, core,
E2, NS3, NS4B, and NS5B, the responders had the highest
distances between samples, relapsers were intermediate, and
nonresponders had the lowest distances. The second pattern was
observed in E1, P7, NS4A, and NS5A, where the relapsers were
similar to the nonresponders but the responders had higher
distances. The single exception to these two patterns was in NS2,
Figure 3. Protein distance among the nonresponder and
relapsers sequences. The mean protein distance among the
nonresponders and relapsers was compared, and the statistical
significance was evaluated using the Mann-Whitney test. A) Pre-
therapy. B) Post-therapy.
doi:10.1371/journal.pone.0002123.g003
Figure 4. Protein distance in pre- and post-therapy samples.
Comparison of pre- and post-therapy protein distances in A)
nonresponders and B) relapsers. Statistical significance was determined
using the Mann-Whitney test.
doi:10.1371/journal.pone.0002123.g004
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nonresponders were significantly lower. When analyzed using
ANOVA, there were differences in all proteins (p,0.005). These
data indicate that a spectrum of variability exists among the
response classes, with responders being the most variable, relapsers
being intermediate, and nonresponders being the least variable.
The most notable exception to this general pattern was NS2,
where relapsers resembled responders.
Evolution of viral sequences during therapy
If differences in viral genetic variability contribute to the
ability of the virus to withstand the pressures induced by therapy,
those isolates that survive therapy would be relatively resistant to
the effects of the drugs whereas those that do not survive would
be sensitive. Resistance could either be present initially or evolve
during therapy. Therefore, we hypothesized that there would be
a difference in evolution between the two groups of sequences,
with relapsers evolving to become more resistant to therapy
while nonresponders would evolve less because they were
initially relatively resistant. To test this hypothesis, paired pre-
and post-therapy sequences from each patient were aligned, and
mutations at the amino acid level that occurred during therapy
were identified. Contrary to our expectations, nonresponders
had more mutations in the polyprotein than the relapsers
(Figure 6A), but this difference was located entirely in E2. Two
regions of E2 were analyzed in detail due to their potential to
affect the outcome of therapy: HVR1 and PePHD. HVR1
(amino acids 384–410) encodes a decoy B-cell epitope [35]. In
HVR1, the nonresponders had 56 mutations in nine of ten
samples, while relapsers had 32 mutations in six of ten samples
(p.0.1 by the Mann-Whitney test). The PePHD region (amino
acids 659–670) can bind to PKR and inhibit its activity [36,37],
but there were no changes in the PePHD region in either the
nonresponders or the relapsers.
To assess the likelihood that these mutations may have altered
the activity of the proteins, the BLOSUM90 scores for each
mutation were evaluated. BLOSUM scores are log-odds ratios of
amino acid substitutions. Substitutions which occur more often
than expected have positive scores and reflect conservative
changes, and substitutions which occur less often than expected
have negative scores and reflect non-conservative changes. For all
proteins except NS2, the scores in nonresponders and relapsers
were not significantly different. In NS2, relapsers had significantly
lower scores than nonresponders by the Kolmogorov-Smirnov test
(p=0.023) (Figure 6B). We next examined the distribution of the
BLOSUM90 scores for each gene. Most of the plots for relapsers
and nonresponders were quite similar. An example is for E2 in
Figure 6C, where there was a difference in the total number of
mutations in relapsers and nonresponders, but the BLOSUM90
score distribution was similar. However, differences in the score
distribution were evident for NS2 (Figure 6D). All of the mutations
in nonresponders had scores ranging from 21 to 3, with a
relatively even distribution throughout that range. In contrast,
most of the scores for relapsers ranged from 22 to 0. Together,
these data indicate that the mutations in the relapsers were more
likely to affect the function of NS2 than the mutations in the
nonresponders.
Locations of mutations on the known protein structures
Crystal structures have been determined for all or part of NS2
[38], NS3 [39], NS5A [40], and NS5B [41]. Mutations that
occurred during therapy were mapped onto these structures, and
the distribution of changes was analyzed by visual inspection and
comparisons to known functional sites and secondary structures on
the protein. No clear differences were noted in the distributions of
mutations from nonresponders and relapsers.
Patterns of positive selection during therapy
To determine if there was a difference in the degree or pattern
of positive selection between nonresponders and relapsers during
therapy, we measured the nonsynonymous to synonymous
substitution ratio (dN/dS) by the Nei-Gojobori method in each
patient and compared the ratios between nonresponders and
relapsers using the Mann-Whitney test. For the entire polyprotein,
nonresponders had higher dN/dS ratios than relapsers (p=0.008)
(Figure 7A). However, this difference was distributed widely
throughout the viral genome, and hence no individual gene
achieved statistical significance.
Many different selective pressures could be applied to the HCV
genome by the pleiotropic effects of interferon and ribavirin.
Negative selection maintains critical functions in many positions,
and positive selection would affect specific regions of proteins
associated with differences in response to the therapy. However,
because all genes in the HCV genome are linked, positive selection
at any given site could co-select neutral variations throughout the
genome. Therefore, to determine if there were small regions of the
protein that were under positive selective pressure, we examined
the dN/dS ratio by the Li-Kimura method in overlapping
windows of 10 codons. Seven of ten nonresponders and seven of
ten relapsers had regions of positive selection (dN/dS .1), and
these regions were distributed throughout the viral genome
(Figure 7B). The polyproteins of nonresponders had 43 regions
of positive selection while relapsers had 23 regions, but this
difference was not statistically significant. Furthermore, there were
no apparent differences between the two groups in any gene
except E2, where nonresponders had more regions of positive
selection in E2 than the relapsers (27 vs. 10) (p.0.05). Therefore,
most nonresponder and relapser sequences evolved in response to
Figure 5. Protein distance in nonresponders, relapsers, and
responder pre-therapy sequences. Comparison of the protein
distances in three-phenotypes of patients.
doi:10.1371/journal.pone.0002123.g005
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in nonresponders than in relapsers.
Quasispecies breadth
HCV replicates as a quasispecies, but our analyses were
performed on the consensus sequence. Therefore, to determine
if there were differences in the quasispecies breadth between the
nonresponder and relapser sequences, we evaluated the prevalence
of mixed base positions in the sequence traces of the uncloned
sequencing templates using the method developed by A. F. Poon
[42]. This method cannot identify a dominant quasispecies
sequence, but it can measure the breadth of the quasispecies at
each nucleotide position by identifying the positions where the
dominant nucleotide is present at less than 80% frequency.
Patterns of quasispecies variation in E2 have been well
characterized in many studies, especially in HVR1 [43–47]. Thus,
we compiled the sequences from E2 for each sample, and
compared the numbers of mixed bases found in nonresponders
versus relapsers using the Mann-Whitney test. The nonresponders
had more mixed base positions than relapsers both pre- and post-
therapy (p=0.004 and p=0.007 respectively) (Figure 8A).
Genetic bottlenecks decrease the genetic breadth within a
population, and a decrease in the diversity of both nonresponders
and relapsers was observed, consistent with both groups passing
through a bottleneck. However, the decline in diversity would be
expected to be greater in those populations that pass through a
tighter bottleneck. Thus, we expected the proportions of mixed
bases retained in the post-therapy samples relative to pre-therapy
samples to be lower in relapsers than in nonresponders. When the
proportions of mixed bases were compared, the relapsers had the
expected greater decline in mixed bases from pre- to post-therapy
samples than the nonresponders, but this difference was not
statistically significant by the Mann-Whitney test (p=0.079)
(Figure 8B).
Figure 6. Mutations in nonresponder and responder sequences over the course of therapy. A) The number of changes in nonresponders
and relapsers were compared using Mann-Whitney test. One relapser does not appear on the chart (113 changes). B) The sums of the BLOSUM90
score for all of the changes occurring in a given sample were compared between nonresponders and relapsers. Totals were compared using a
Kolmogorov-Smirnov test. C) Distribution of BLOSUM90 scores for E2. D) Distribution for BLOSUM90 scores for NS2.
doi:10.1371/journal.pone.0002123.g006
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Failure of interferon plus ribavirin therapy for HCV can occur
in two different patterns: nonresponse and relapse. HCV is highly
diverse genetically, and this diversity could affect how the virus
responds to therapy. Furthermore, HCV can evolve rapidly, and
hence therapy could drive evolution of the virus by selecting
relatively resistant variants. We previously found that high genetic
diversity in genotype 1a pre-therapy NS3 and NS5A sequences
correlated robustly with response to therapy [32]. The previous
study addressed variability related to both response to therapy and
the race of the patient. Here, we employed the pre- and post-
therapy sequences from genotype 1a Virahep-C treatment failures
to evaluate both the extent to which variations in viral protein
sequences may affect the pattern of failed therapy and to
determine the effects of failed therapy on the viral sequences.
Issues of variability associated with the race of the patient were not
addressed in this study because the low number of samples
available does not provide enough power to make useful
comparisons.
To evaluate how the viral protein sequences changed during
treatment, we examined the number and pattern of amino acid
mutations that occurred in each sequence during therapy. We
expected to find a relatively high mutation frequency due to
HCV’s high genetic plasticity, but contrary to our expectations,
the 0.9% mutation frequency observed in the samples was
relatively small in relation to the variability among independent
HCV isolates (10–12%), and was in the range of quasispecies
variability typically found in a given individual (,1–4%).
Furthermore, about one third of the mutations we observed were
in E2, especially in HVR1, so the mutation rate of the HCV ORF
outside E2 was just 0.59%. Thus, a primary conclusion of this
study is that the HCV consensus sequence is relatively stable
during failed antiviral therapy. Most previous studies of HCV
evolution during therapy have focused on small regions of the
genome, primarily in NS5A and E2, and especially on the highly
variable regions in these genes [23,48–52]. These regions were
chosen because their high variation makes them ideal for
Figure 7. The dN/dS is similar in nonresponders and relapsers.
A. Comparison of dN/dS ratios between nonresponders and relapsers.
dN/dS was determined by the Nei-Gojobori method. B. dN/dS in ten
codon windows as determined by SWAPSC using the Li-Kimura method.
Each sample is represented by a different color and each dot indicates a
specific 10 codon window. Regions of positive selection are overlapping
10 codon windows with dN/dS .1, and are denoted as a collection of
points on the graph forming an upward spike.
doi:10.1371/journal.pone.0002123.g007
Figure 8. Quasispecies breadth is lower in relapser than
nonresponder sequences. Nonresponder and relapser sequences
were analyzed using Phred and positions at which the dominant
nucleotide was present at ,80% frequency were determined. A)
Number of positions of quasispecies diversity in nonresponders and
relapsers in pre- and post-therapy samples. B) Proportion of positions of
mixed nucleotides in post-therapy samples relative to pre-therapy
samples. One nonresponder (3.22) and one relapser (10.00) are not
shown. The relapser is the same as was removed from Figure 3A.
doi:10.1371/journal.pone.0002123.g008
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the unintended effect of helping to form the perception that HCV
sequences are similarly mutable throughout the genome.
The second major conclusion from this study was that genetic
differences in NS2 correlated with the pattern of failed response to
interferon-based therapy. These correlations were evident in the
number of pre-therapy unique variations (Figure 2), the pre-
therapy protein distance (Figure 3), and the nature of mutations
that occurred during therapy (Figure 6B and D). Relapsers had
higher variability in NS2 than nonresponders in pre-therapy
samples, and mutations that occurred in NS2 over the course of
therapy were more likely to affect the function of the protein in
relapsers than in nonresponders. Therefore, variability in NS2
may help determine whether a patient will be a nonresponder or
relapser. However, this possibility is difficult to interpret at a
functional level because the roles of NS2 in viral replication and
pathology are poorly understood. NS2 has been shown to inhibit
the interferon response when expressed in cells [53], and the
observed differences in variability could lead to differences in the
effectiveness of this inhibition. Alternatively, since NS2 is involved
in protein processing and is required for virion formation [54],
variability could also affect the effectiveness of viral protein
processing and virus production. Further study of NS2, including
identifying possible cellular targets, may clarify how NS2 affects
response to interferon-based therapy.
Despite the overall stability of the HCV sequences, a substantial
number of mutations did occur during failed therapy, but no
significant difference was observed in the number of mutations
between the nonresponders and relapsers (Figure 6A). We had
hypothesized that relapsers would evolve more than nonrespond-
ers as the virus adapted to the pressures of therapy. This was not
observed at the level of the number of mutations, possibly because
both groups passed through at least a weak bottleneck. However,
despite equivalent numbers of mutations in the relapser and
nonresponder groups, the overall intra-group genetic distance in
the relapsers increased while it did not change in nonresponders
(Figure 4). Therefore, the mutations in relapsers created new
sequences, whereas those in nonresponders largely alternated
between sequences already present within the group.
To determine which sequence motifs may have been under
positive selection during therapy, we examined the dN/dS ratio in
a sliding window of ten codons. Many regions of strong positive
selection were observed (Figure 7B), but the number and
distribution of regions of positive selection were similar in the
nonresponder and relapser sequences. This implies that both
nonresponders and relapsers evolved to similar degrees under the
pressures induced by therapy and that the targets of the selective
pressure were broadly distributed throughout the polyprotein. The
exception to this pattern was in E2, where there were more regions
of positive selection in nonresponders than in relapsers. As E2 is a
primary target of humoral immune responses, this difference may
be due to the difference in neutralizing antibody titers throughout
therapy. Brown et al. showed that E2 and not E1 evolve in
chronically infected patients in solvent exposed regions [55], and
our data show that there were differences in evolution of the
nonresponder and relapser sequences. Since the nonresponders
had relatively high viral titers throughout therapy, the humoral
immune response may have been be constantly stimulated by a
relatively high antigen load, leading to an evolving humoral
pressure. In relapsers, viral titers declined below the detection
limit, and the humoral immune response may have declined
during therapy due to the drop in antigen load. These analyses
compared pre- and post-therapy sequences, and the patterns of
evolution observed in samples during therapy may be different
than those that were prevalent in post-therapy samples. Therefore,
studies of samples from sustained viral responders, nonresponders,
and relapsers at early time-points during therapy, such as 2 or 4
weeks, could be useful in further understanding the evolution of
these groups in response to interferon-based therapy. However,
the relatively small number of changes observed in the viral
consensus sequence between the pre- and post-therapy time points
implies that a detailed quasispecies analysis over the early phases
of therapy would be needed to substantially advance this
understanding.
Genetic bottlenecks can cause a constriction of the genetic
variability within a population. In HCV, this is reflected in the
breadth of the quasispecies within an individual. We expected the
difference in the strength of the bottlenecks experienced by
nonresponder and relapser groups to cause a greater decline in the
quasispecies breadth in the relapsers. We found that the intra-
patient quasispecies breadth declined in both nonresponders and
in relapsers, and that the decline in relapsers was greater than in
nonresponders, but this difference did not reach statistical
significance (Figure 8B). Other groups have shown that the
breadth of the quasispecies is correlated with response to
interferon-based therapy [44,46]. Our study indicates that changes
in the breadth of the quasispecies also correlated with the
difference in response between nonresponders and relapsers.
This study was designed to assess that role of HCV genetic
variation at the protein level on outcome of therapy. Variability in
the RNA itself can also predicted to affect the response to therapy
by altering the RNA structure or the interactions of the RNA with
host proteins and/or the viral replication machinery. RNA
elements associated with protein binding could occur anywhere
in the viral RNA, but they are most likely to occur in the 39 and 59
UTRs since these areas are known to contain the promoters for
viral replication and the viral internal ribosome entry site. The
sequences obtained for this study include part of the UTRs, but
these sequences are of varying length, and in some cases are
absent. This precludes meaningful analysis of these samples
outside the ORF.
This study is the largest examination to date of genetic changes
in the full-length viral open-reading frame during interferon-based
therapy, and it is the first study comparing nonresponders to
relapsers in genotype 1a. Previous studies have examined the
changes in patient samples over the course of therapy. Enomoto
identified the ISDR [56] by examining pre- and post-therapy
sequences in full-length sequences from three nonresponding
genotype 1b infected patients. The three patients also had many
mutations scattered elsewhere throughout the structural and
nonstructural genes. We saw similar patterns of mutations in the
1a sequences. Other studies of evolution during therapy focused
on smaller portions of the genome. Vuillermoz examined the
changes in genotype 1b responders, nonresponders, and break-
through patients in E2, NS5A, and NS5B [57]. They showed
higher mutation rates in responders in the V3 region of NS5A
(amino acids 2356-2379) and conservation of the PePHD region in
E2 in all samples. We also found no mutations in the PePDH
region, but unlike Vuillermoz, we did not find a difference
between nonresponders and relapsers in the V3 region. Differ-
ences in the observed numbers of mutations between our study
and the Vuillermoz study could be due to the different genotypes
studied or the different definitions of the response types analyzed.
Evolution of HCV during therapy has also been noted in NS5B
[58], NS5A [23,50,52], and in the structural proteins, especially
HVR1 [48–52]. While correlations between diversity and
evolution between relapsers and nonresponders were noted in
some of these studies, others showed no difference between the
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NS5B between the nonresponders and relapsers but we did find
many regions of positive selection in E2 as well as HVR1, similar
to earlier studies.
Genetic variability between HCV genotypes can lead to
difference in response to therapy (e.g. genotype 1 vs. 2), and we
have shown that variability differences are also associated with
early response to therapy within a given viral subgenotype [32].
Here, we divided the nonresponders into two phenotypes,
nonresponders and relapsers, and found a spectrum of diversity
associated with failed response to antiviral therapy, where
relapsers fell between responders and nonresponders. We interpret
this pattern to indicate that viral variability forms a continuum
from sequences that are close to an ‘‘optimal’’ sequence to
sequences that are more divergent. The optimal sequence would
be most resistant to the effects of therapy, and the degree of
resistance would decline with genetic distance from the optimum.
Those samples that were furthest from the optimum sequence
would be unable to withstand the super-physiological interferon
response induced by therapy, and hence would be cleared.
Therefore, although variability of the virus is clearly not the only
factor affecting response to therapy, it appears to play an
important role in determining the pattern of response of HCV
to interferon-based therapy. Further sequencing of isolates that are
nonresponders to therapy and characterization of these sequences
in in vitro studies could reveal this optimum sequence, and in vitro
studies of this sequence could reveal how HCV inhibits the type 1
interferon response. Understanding how the HCV proteins are
involved in resistance to interferon and ribavirin could identify
new drug targets that improve or replace the current therapy.
Materials and Methods
Virahep-C
Virahep-C was a multi-center clinical study of peginterferon a-
2a and ribavirin therapy in treatment naı ¨ve patients chronically
infected with HCV genotype 1 [8]. Virahep-C included 205
Caucasian American and 196 African American participants, all of
whom were treated with peginterferon a-2a (Pegasys
TM, Roche
Pharmaceuticals; 180 mg weekly by self-administered subcutane-
ous injection) and ribavirin (Copegus
TM, Roche Pharmaceuticals;
1000 mg/day for those ,75 kg and 1200 mg/day for those $75
kg, orally). Treatment was for 24–48 weeks depending on
detection of viral titers at 24 weeks. Serum RNA levels were
quantified as described previously [8], and the primary outcome
was sustained viral response, undetectable viremia at 24 weeks
post-therapy. All patients gave written informed consent to the
Virahep-C study and its integral basic science studies, and this
project was approved by the Saint Louis University Institutional
Review Board. The CONSORT checklist and CONSORT flow
chart are available as supporting information; see Figure S1 and
Checklist S1.
Sequencing
Consensus sequences for the full HCV ORF were obtained by
direct sequencing of overlapping nested RT-PCR reactions as
described previously [59]. Pre-therapy sequences were deter-
mined from samples taken just prior to the beginning of therapy.
Post-therapy sequences were determined from samples collected
6 months following cessation of therapy. Post-therapy sequences
were generated using conditions identical to those used in the
pre-therapy samples to minimize amplification bias. When post-
therapy sequences could not be obtained using the conditions
previously employed for the pre-therapy samples [32], pre-
therapy samples were resequenced using the primers and
conditions that were used to amplify the post-therapy samples.
When necessary, an alternate amplification method developed
by Fan et al. involving long RT-PCR was used to amplify both
pre- and post-therapy samples [60]. Pre-therapy samples were
resequenced for samples 1013, 1030, 2011, 2027, 4025, 4035,
5009, 6018, 7002, 7003, 7040, 7041, and 7043. These sequences
differed by ,0.1% at the amino acid level from our previously
reported sequences [32]. This amplification bias is within the
0.6% we reported for HCV genetic analyses and represents
alternate samplings of the quasispecies spectrum [59]. The
analysis included all but the final 56 amino acids of the open-
reading frame because sequencing of the full ORF was not
possible for 11 samples. The sequences have been deposited in
Genbank, and are listed in Table 3.
Sequence analysis
Amino acid sequences were deduced from nucleic acid
sequences. Sequence alignments were done with ClustalW. The
ARF gene was not analyzed due to differences in length of the
protein in individual isolates. Amino acid positions that varied
relative to the genotype 1a population consensus sequence [32]
were identified using Mutation Master [61]. The genotype 1a
consensus was derived from all 12 full-length ORFs in the Los
Alamos National Laboratory and European HCV database [62] in
April, 2005 that were from different patients, plus 5 additional 1a
ORFs we sequenced from non-Virahep-C cohorts. The mean
genetic distance was calculated using the p-distance algorithm in
the MEGA3 DNA analysis package [63]. dN/dS ratios at the gene
and whole-ORF levels were calculated with the MEGA3 DNA
analysis package using the Nei-Gojobori method. dN/dS ratios in
Table 3. Patient numbers, response class, and GenBank
accession numbers for pre- and post-therapy sequences.
Patient Response* Pre-therapy Post-therapy
1013 N EU362899 EU362876
1024 N EF407428 EU362877
1030 N EU362900 EU362878
2005 R EF407452 EU362879
2011 R EU362901 EU362880
2027 R EU362902 EU362881
4025 R EU362903 EU362883
4035 N EF407453 EU362884
5009 N EU362904 EU362885
5014 N EF407435 EU362886
6020 R EF407450 EU362887
6025 N EU362905 EU362888
6030 R EU362906 EU362889
7002 R EU362907 EU362890
7003 N EU362908 EU362891
7012 N EF407438 EU362892
7040 N EU362909 EU362893
7041 R EU362910 EU362894
7043 R EU362911 EU362895
7046 R EF407433 EU362896
*N, nonresponders. R, relapsers.
doi:10.1371/journal.pone.0002123.t003
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Kimura method [64].
Quasispecies breadth
The sequence, quality, and polymorphisms in trace files of the
first 1064 nucleotides of E2 were compiled for all 20 samples using
Phred [65,66]. Each trace file was converted into a single sequence
file using a script provided by Dr. Art Poon [42] with positions
where the dominant nucleotide was present at less than 80%
maximum being indicated as polymorphisms. The numbers of
mixed bases were determined using Clone Manager (Sci-Ed
Software).
Statistical analyses
The average genetic distance and numbers of unique variations
between samples were compared using the Mann-Whitney test.
BLOSUM90 scores were compared using the Kolmogorov-
Smirnov test. A p-value of #0.05 was considered statistically
significant. Statistical analyses were performed using SAS software
or SPSS v. 13.0.
Supporting Information
Checklist S1 CONSORT type checklist for the viral evolution
study within the Virahep-C study.
Found at: doi:10.1371/journal.pone.0002123.s001 (0.05 MB
DOC)
Figure S1 CONSORT flowchart. A depiction of how patients
were selected from the main Virahep-C study for this study on
viral evolution.
Found at: doi:10.1371/journal.pone.0002123.s002 (5.63 MB
DOC)
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